Vol 13, No 3 (2020)
Prace poglądowe
Published online: 2020-10-02

open access

Page views 523
Article views/downloads 1335
Get Citation

Connect on Social Media

Connect on Social Media

Hypoxia — inducible factor prolyl hydroxylase inhibitors (HIF-PHI) — a breakthrough in treatment of anemia in patients with chronic kidney disease?

Łukasz Jankowski, Magdalena Durlik
Forum Nefrologiczne 2020;13(3):116-120.

Abstract

Anemia is the common complication of chronic
kidney disease (CKD). Insufficient secretion of
erythropoietin by damaged kidneys and disorders
of iron management (including increased hepcidin
concentration) play a major role in it’s pathophysiology.
Classical treatment of anemia in patients with
CKD bases on the correction of iron deficiencies
and administration of erythropoiesis stimulating
factors (ESAs) — analogues of human erythropoietin.
In 1992 Semenze and Wang for the first time
discovered the molecule activating gene expression
for erythropoietin — the hypoxia-induced HIF-1 transcription
factor, which paved the way for research
into new ways of treating anemia in patients with
CKD. In the article the current state of knowledge regarding
the mechanism of action and the clinical usage
of new drugs — hypoxia-inducible factor prolyl
hydroxylase inhibitors (HIF-PHI) — in the treatment
of anemia in patients with CKD was described.

Article available in PDF format

View PDF (Polish) Download PDF file



Renal Disease and Transplantation Forum